Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 53, Issue 3, 2001, Pages 141-148

  Van Gaal, Luc F ^a   Van Acker, Kristien L ^a   De Leeuw, Ivo H ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Mealtime insulin secretion; Oral hypoglycaemic agents; Prandial glucose regulation; Repaglinide; Type 2 diabetes

Indexed keywords

FRUCTOSAMINE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; PLACEBO; REPAGLINIDE; SULFONYLUREA;

ADULT; ARTICLE; CAPILLARY BLOOD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TEST MEAL;

AREA UNDER CURVE; BLOOD GLUCOSE; CARBAMATES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FASTING; FRUCTOSAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MIDDLE AGED; PIPERIDINES; PLACEBOS; POSTPRANDIAL PERIOD; TIME FACTORS;

EID: 0034898982     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(01)00253-4     Document Type: Article

References (30)

1. Non-insulin-dependent diabetes mellitus
2. Sulphonylurea antidiabetic drugs, an update of their clinical pharmacology and rational therapeutic use
3. Incidence of severe side effects during therapy with sulfonylureas and biguanides
4. Diabetes in the elderly: Diagnosis, pathogenesis, and therapy
5. Diabetic renal disease
6. A desktop guide to type 2 diabetes mellitus
7. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus
8. A glimpse of the 'natural history' of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis
9. Insulin secretion and sensitivity in newly diagnosed NIDDM Caucasians in the UK
10. Metabolic abnormalities in impaired glucose tolerance
11. The postprandial state and risk of cardiovascular disease
12. The clinical importance of postprandial glucose
13. The importance of hyperglycaemia in the non-fasting state to the development of cardiovascular disease
14. The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications
15. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up
16. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose
17. European diabetes epidemiology group, glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria
18. Mechanism of action of AG-EE 623 ZW, a novel insulinotropic agent
19. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea treated patients with NIDDM
20. Repaglinide: A new short-acting insulinotropic agent for the treatment of type 2 diabetes
21. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes
22. + concentrations
23. Repaglinide treatment is associated with significantly less severe hypoglycaemic events compared to sulphonylurea
24. Review of prandial glucose regulation with repaglinide: A solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
25. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
26. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomised prospective 6-year study
27. Prospective randomised study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus
28. Flexible meal-related dosing with repaglinide facilitates glycaemic control in therapy-naïve type 2 diabetes
29. Prandial glucose regulation with repaglinide: Its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes